Atorvastatin: A pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events

PharmacoEconomics

Volumn 25, Issue 12, 2007, Pages 1031-1053

  Plosker, Greg L ^a   Lyseng Williamson, Katherine A ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

Adis Drug Evaluations; Atorvastatin, general; Cardiovascular disorders, treatment; HMG CoA reductase inhibitors, general

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; FACTORIAL ANALYSIS; FLATULENCE; HAZARD RATIO; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; MEDICAL CARE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SURVIVAL;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; RISK FACTORS;

EID: 36749099016     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725120-00005     Document Type: Review

References (85)

1. Walsh J, Ostrow N. Pfizer earns $2.86 bln on Lipitor sales; Merck's profit slips [online]. Available from URL: http://quote.bloomberg.com [Accessed 2007 Aug 30]
2. Ma J, Sehgal NL, Ayanian JZ, et al. National trends in statin use by coronary heart disease risk category. PLoS Med 2005 May; 2 (5): e123
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 Jun 28; 326 (7404): 1423-9
4. Skinner JS, Cooper A, Feder GS. Secondary prevention for patients following a myocardial infarction: summary of NICE guidance. Heart 2007 Jul; 93 (7): 862-4
5. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998 Mar 1; 81 (5): 582-7
6. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs 2007; 67 Suppl. 1: 3-15
7. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003 Jul 15; 92 (2): 152-60
8. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001 Aug 15; 111 (3): 185-91
9. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002 Dec; 144: 1044-51
10. American Heart Association. Cardiovascular disease statistics [online]. Available from URL: http://www.americanheart.org [Accessed 2007 Aug 30]
11. American Heart Association. Cholesterol statistics [online]. Available from URL: http://www.americanheart.org [Accessed 2007 Aug 30]
12. American Heart Association. Cardiovascular disease cost [online]. Available from URL: http://www.americanheart.org [Accessed 2007 Aug 30]
13. Leal J, Luengo-Fernández R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006 Jul; 27 (13): 1610-9
14. Luengo-Fernández R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006 Oct; 92 (10): 1384-9
15. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006 May 27; 367 (9524): 1747-57
16. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361 (9364): 1149-58
17. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685-96
18. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevenon tion after myocardial infarction: the IDEAL study. A randomized controlled trial. JAMA 2005 Nov 16; 294 (19): 2437-45
19. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 Apr 7; 352 (14): 1425-35
20. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Proquote. gram goal versus 'usual' care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18 (4): 220-8
21. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes, the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (5): 1711-8
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15): 1495-504
23. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999 Jul 8; 341 (2): 70-6
24. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2004 Aug 10; 110 (6): 674-8
25. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007 Mar 27; 49 (12): 1272-8
26. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004 Nov 2; 44 (9): 1772-9
27. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 Aug 10; 355 (6): 549-59
28. Gaspardone A, Arca M. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs 2007; 67 Suppl. 1: 29-42
29. Gaspardone A. Atorvastatin: its clinical role in cerebrovascular prevention. Drugs 2007; 67 Suppl. 1: 55-62
30. Lipitor® (atorvastatin calcium) tablets. US prescribing information. New York: Pfizer Inc., 2007 Mar
31. Arca M. Atorvastatin: a safety and tolerability profile. Drugs 2007; 67 Suppl. 1: 63-9
32. Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003 Sep 15; 92 (6): 670-6
33. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006 Jan 1; 97 (1): 61-7
34. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007 Feb; 99 (3): 379-81
35. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005 Jun 14; 111 (23): 3051-7
36. Lachaine J, Merikle E, Tarride JE, et al. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Clin Ther 2007 Mar; 29 (3): 519-28
37. Maclaine GD, Patel H. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. Int J Clin Pract 2001 May; 55 (4): 243-9
38. Plans-Rubio P. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Am J Cardiovasc Drugs 2006; 6 (3): 177-88
39. Smith DG, McBurney CR. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Pharmacoeconomics 2003; 21 Suppl. 1: 13-23
40. Wilson K, Marriott J, Fuller S, et al. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmacoeconomics 2003; 21 Suppl. 1: 1-11
41. Tarraga-Lopez PJ, Celada-Rodriguez A, Cerdan-Oliver M, et al. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain. Pharmacoeconomics 2005; 23 (3): 275-87
42. Benner JS, Smith TW, Klingman D, et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health 2005; 8 (6): 618-28
43. Hirsch M, O'Donnell JC, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil 2005 Feb; 12 (1): 18-28
44. Hirsch M, O'donnell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol 2005 Oct 10; 104 (3): 251-6
45. Chong PH, Varner D. Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. Pharmacotherapy 2005 Feb; 25 (2): 270-8
46. Miller PS, Smith DG, Jones P. Cost effectiveness of rosuvastain tin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US analysis of the STELLAR trial). Am J Cardiol 2005 Jun 1; 95 (11): 1314-9
47. Ohsfeldt RL, Gandhi SK, Fox KM, et al. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care 2006 Nov; 12 Suppl. (15): S412-23
48. Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003 Nov; 57 (9): 792-800
49. Tran YB, Frial T, Miller PS. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol 2007 Summer; 14 (2): e205-14
50. Lindgren P, Buxton M, Kahan T, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 2005 Feb; 12 (1): 29-36
51. Davies A, Hutton J, O'Donnell J, et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006; 13 (3): 196-202
52. Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001 Spring; 8 (1): 9-16
53. Raikou M, McGuire A, Colhoun HM, et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin tatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007; 50 (4): 733-40
54. Fernández de Bobadilla J, Lopez de Sa E, Alonso Troncoso I, et al. Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study [in Spanish]. An Med Interna 2006 May; 23 (5): 213-9
55. Brandle M, Davidson MB, Schriger DL, et al. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003 Jun; 26 (6): 1796-801
56. Ramsey SD, Clarke LD, Roberts CS, et al. An economic evaluation of atorvastatin in primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008; 26. In press
57. Calvo Gómez C, Fernández de Bobadilla J, García Vargas M, et al. Coste-efectividad de atorvastatina en hipertensos con riesgo moderado: evaluación económica del estudio ASCOT-LLA. Pharmacoeconomics Spanish Research Articles 2006; 3 (3): 123-35
58. Fernández de Bobadilla J, Calvo Gómez C, Gómez-Gerique JA, et al. Coste por año de vida ganado con atorvastatina 10mg en pacientes hipertensos españoles en riesgo moderado: evaluación económica del estudio ASCOT-LLA con costes españoles. Pharmacoeconomics Spanish Research Articles 2007; 4 (1): 11-24
59. Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007 May 8; 115 (18): 2398-409
60. Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 2007 Jun; 28 (12): 1448-53
61. Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm 1999 Sep 1; 56 (17): 1726-32
62. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Scandinavian Simvastatin Survival Study Group. Lancet 1994 Nov 19; 344 (8934): 1383-9
63. Brosa Riestra M, Crespo Palomo C. Análisis coste-efectividad del manejo protocolizado de la dislipemia mediante atorvastatina versus práctica clinica habitual en prevención secundaria de enfermedad cardiovascular. Revista Española De Economía De La Salud 2004 Feb; 3 (1): 50-6
64. Schwartz GG, Ganz P, Waters D, et al. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol 2003 Nov 1; 92 (9): 1109-12
65. Buller N, Gillen D, Casciano R, et al. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003; 21 Suppl. 1: 25-32
66. Casciano R, Tarride JE, Breton MC, et al. A pharmacoeconomic evaluation of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in Canada. Can J Clin Pharmacol 2004 Spring; 11 (1): e179-90
67. Olsson A, Casciano R, Stern L, et al. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 2004 Jul; 96 (1): 51-7
68. Gomez-Gerique JA, Casciano R, Stern L, et al. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. Eur J Health Econ 2004 Oct; 5 (3): 278-84
69. FXConverter - Currency converter for 164 countries [online]. Available from URL: http://www.oanda.com/convert/classic [Accessed 2007 Sep 7]
70. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 2004 Sep 15; 292 (11): 1307-16
71. Fernández de Bobadilla J, García Vargas M. Análisis coste-efectividad del tratamiento intensivo con atorvastatina 80 mg vs. pravastatina 40 mg en el síndrome coronario agudo: una evaluación económica basada en el estudio PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy). Pharmacoeconomics-Spanish Research Articles 2006; 3 (1): 19-30
72. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002 Jul 16; 106 (3): 388-91
73. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Circulation 2006 Jun 20; 113 (24): e873-923
74. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006 May 16; 113 (19): 2363-72
75. National Institute for Clinical Excellence. MI: secondary prevention (NICE clinical guideline 48) [online]. Available from URL: http://www.nice.org. wk [Accessed 2007 Sep 13]
76. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: executive summary. Circulation 2007 Oct 23; 116 (17): 803-77
77. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7 (5): 518-28
78. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001 Dec; 323 (7324): 1300-3
79. National Institute for Clinical Excellence. NICE (2004) guide to the methods of technology appraisal (reference N0515) [online]. Available from URL: http://www.nice.org.uk [Accessed 2007 Sep 19]
80. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life Agand why doesn't it increase at the rate of inflation? Arch Intern Med 2003 Jul 28; 163: 1637-41
81. Jónsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
82. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11 (14): 1-184
83. Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997 Jan 30; 336 (5): 332-6
84. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001 May; 141 (5): 727-34
85. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996 Jul; 17 (7): 1001-7